Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Insulet Corp
(NQ:
PODD
)
193.30
+2.42 (+1.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Insulet Corp
< Previous
1
2
3
4
5
6
7
Next >
Coinbase, DoorDash And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
November 04, 2022
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Insulet Shares Jump After Q3 Earnings Surpass Expectations, Improved Annual Guidance
November 04, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
October 18, 2022
Upgrades
Via
Benzinga
FDA Approves Insulet's Omnipod Automated Insulin System For Patients Two Years & Above
August 22, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
October 12, 2022
Upgrades
Via
Benzinga
What 8 Analyst Ratings Have To Say About Insulet
August 05, 2022
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:
Via
Benzinga
Insulet Posts Q2 Revenue Beat, Lifts FY22 Guidance
August 05, 2022
Via
Benzinga
5 Analysts Have This to Say About Insulet
June 24, 2022
Insulet (NASDAQ:PODD) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Analyst Ratings for Insulet
October 12, 2022
Over the past 3 months, 6 analysts have published their opinion on Insulet (NASDAQ:PODD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Neurocrine Leads 5 Stocks To Watch In Sickly Market
September 03, 2022
Neurocrine Biosciences leads five medical stocks showing resilience.
Via
Investor's Business Daily
A Bullish Sign Appears On Insulet's Chart
September 01, 2022
If history is any guide, there may be good fortune ahead for shares of Insulet (NASDAQ:PODD). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...
Via
Benzinga
$1000 Invested In Insulet 5 Years Ago Would Be Worth This Much Today
August 23, 2022
Insulet (NASDAQ:PODD) has outperformed the market over the past 5 years by 24.25% on an annualized basis producing an average annual return of 35.42%. Currently, Insulet has a market capitalization of...
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 22, 2022
Via
Benzinga
4 Analysts Have This to Say About Insulet
June 07, 2022
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:
Via
Benzinga
Expert Ratings for Insulet
May 06, 2022
Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings:
Via
Benzinga
Benzinga Before The Bell: Apple Employees Resist Calls For Return-To-Office, Tesla About To Hike FSD Prices Again, MGM China Injects $594M Into Macau Unit And Other Top Financial Stories Monday, August 22
August 22, 2022
Reuters Vodafone To Sell Hungarian Business For $1.8B: Report
Via
Benzinga
FDA Clears Insulet's Omnipod 5 Automated Insulin Delivery System For Preschool Children
August 22, 2022
The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ: PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with...
Via
Benzinga
Recap: Insulet Q2 Earnings
August 04, 2022
Insulet (NASDAQ:PODD) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Insulet missed estimated earnings by...
Via
Benzinga
7 Stocks to Buy That Could Make You a Millionaire
June 23, 2022
These seven of the best stocks to buy in June. TXG, BRKR, ETSY, PODD, MAR, RH and SEDG can make excellent investments.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
July 11, 2022
Upgrades
Via
Benzinga
Comparing Fitbits To Medical Devices? This Company Says Things Aren't Even Close
June 16, 2022
The health and wellness industry focused on the well-being of the body, mind and spirit has captured the globe's attention. According to management consulting firm, Mckinsey & Co., the global wellness...
Via
Benzinga
Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks
May 31, 2022
The deal would have been transformative, but may have limited teamwork in the space.
Via
Investor's Business Daily
Looking Into Insulet's Return On Capital Employed
May 26, 2022
According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4.
Via
Benzinga
How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space
May 24, 2022
One analyst called the rumored deal "transformative," but says the timing is unfavorable.
Via
Investor's Business Daily
PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition
May 24, 2022
Insulet (PODD) stock is heading higher on Tuesday as investors react to reports that DexCom (DXCM) is considering acquiring the company.
Via
InvestorPlace
Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg
May 24, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on
May 24, 2022
Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning!
Via
InvestorPlace
Citigroup Maintains Buy Rating for Insulet: Here's What You Need To Know
May 17, 2022
Citigroup has decided to maintain its Buy rating of Insulet (NASDAQ:PODD) and lower its price target from $350.00 to $310.00. Shares of Insulet are trading up 1.23% over the last 24 hours, at $199.34...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
May 17, 2022
Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday.
Via
Benzinga
Recap: Insulet Q1 Earnings
May 05, 2022
Insulet (NASDAQ:PODD) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.